Literature DB >> 6753903

Clinical and haemodynamic responses to captopril and hydralazine in chronic congestive heart failure: the importance of preload reduction.

D J Fitzgerald, W G O'Callaghan, K O'Malley, J Horgan, E O'Brien.   

Abstract

1 Although many vasodilators are effective in the treatment of severe congestive heart failure, there have been few comparative studies of these drugs. We compared the acute haemodynamic effects of captopril and hydralazine in 11 patients with congestive cardiac failure unresponsive to diuretics and digoxin. Both drugs increased resting cardiac index, although this effect appeared more pronounced for hydralazine (33% v 23%). Captopril reduced pulmonary capillary wedge pressure (-8 mm Hg, p less than 0.01) which decreased only slightly on hydralazine. 2 Long-term treatment was then started on the dose found effective during acute administration. Each drug was given for eight weeks. Exercise tolerance improved with both drugs, the increase during the hydralazine phase correlating with the increase in cardiac index at rest (r = 0.75; p less than 0.05). Clinical improvement appeared more definite on captopril than on hydralazine, however. This improvement was maintained during the captopril phase only in those patients who had a greater than 25% reduction in pulmonary capillary wedge pressure in the acute study.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753903      PMCID: PMC1427535          DOI: 10.1111/j.1365-2125.1982.tb02080.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Hydralazine in the management of left ventricular failure.

Authors:  D H Fitchett; J A Neto; C M Oakley; J F Goodwin
Journal:  Am J Cardiol       Date:  1979-08       Impact factor: 2.778

2.  The renin system: Variations in man measured by radioimmunoassay or bioassay.

Authors:  J E Sealey; J Gerten-Banes; J H Laragh
Journal:  Kidney Int       Date:  1972-04       Impact factor: 10.612

3.  Comparative hemodynamic effects of converting enzyme inhibitor and sodium nitroprusside in severe heart failure.

Authors:  T R Vrobel; J N Cohn
Journal:  Am J Cardiol       Date:  1980-02       Impact factor: 2.778

4.  Sustained hemodynamic effects without tolerance during long-term isosorbide dinitrate treatment of chronic left ventricular failure.

Authors:  J A Franciosa; J N Cohn
Journal:  Am J Cardiol       Date:  1980-03       Impact factor: 2.778

5.  Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside.

Authors:  G L Pierpont; J N Cohn; J A Franciosa
Journal:  Chest       Date:  1978-01       Impact factor: 9.410

6.  Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.

Authors:  K Chatterjee; B Massie; S Rubin; H Gelberg; B H Brundage; T A Ports
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

7.  Oral hydralazine therapy for chronic refractory heart failure.

Authors:  K Chatterjee; W W Parmley; B Massie; B Greenberg; J Werner; S Klausner; A Norman
Journal:  Circulation       Date:  1976-12       Impact factor: 29.690

8.  Precipitation of heart failure following sudden withdrawal of hydralazine.

Authors:  J R Black; J Mehta
Journal:  Chest       Date:  1979-06       Impact factor: 9.410

9.  Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients.

Authors:  J A Franciosa; G Pierpont; J N Cohn
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

10.  Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure: evidence for a direct negative chronotropic effect of prazosin.

Authors:  M Packer; J Meller; R Gorlin; M V Herman
Journal:  Am J Cardiol       Date:  1979-08       Impact factor: 2.778

View more
  1 in total

1.  Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine.

Authors:  P M Schofield; N H Brooks; G P Lawrence; H J Testa; C Ward
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.